$IONS (IONIS PHARMACEUTICALS) — 8-K: Ionis partner Roche's Phase 3 IMAgINATION study hits primary endpoint in IgA nephropathy

Sefaxersen achieved statistically significant and clinically meaningful reductions in proteinuria versus placebo at 37 weeks, as measured by 24-hour urine protein-to-creatinine ratio. The Phase 3 study enrolled 459 people randomized 1:1 to sefaxersen or placebo for 105 weeks. The safety profile was consistent with previously reported data, with no new safety signals. The study will continue blinded to evaluate change in kidney function over two years as measured by eGFR at week 105.

Sefaxersen achieved statistically significant and clinically meaningful reductions in proteinuria versus placebo at 37 weeks, as measured by 24-hour urine protein-to-creatinine ratio. The Phase 3 stud